Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Title
Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework
Authors
Keywords
Cerebrospinal fluid, Beta-amyloid, Tau, Phosphorylated tau, Biomarker development, Early diagnosis, Biomarker-based diagnosis, Alzheimer's disease, 5-Phases
Journal
NEUROBIOLOGY OF AGING
Volume 52, Issue -, Pages 196-213
Publisher
Elsevier BV
Online
2017-03-17
DOI
10.1016/j.neurobiolaging.2016.02.034

Ask authors/readers for more resources

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now